Monitoring and evaluation

Cytology

  • Around 160,000 screening smears among women aged 20–64 are taken yearly in Slovenia, while total number of smears in around 220,000.
  • Less than 0.2% of screening smears are unsatisfactory for evaluation, an improvement from more than 5% ten years ago.
  • Almost 95% of screening smears are negative for intraepithelial lesion or malignancy, including 5 % of non-neoplastic changes in 2019.
  • Pathological changes were detected in 5.5% of screening smears, which is a slight increase from previous years. 4.6% were low-grade changes and 0.9% high-grade.
  • In the past 10 years, we managed to lessen the number of screening test from around 179,000 to around 159,000 and still slightly increase exam coverage. This is partially due to less non-satisfactory smears and partially due to better adherence to screening guidelines (intervals).

 

Table: Cytology screening smears by result

 2010201120122013201420152016201720182019
Number of all screening smears (100%)178,804177,788167,563166,279166,067161.203158.241156.374155.927158.916
Satisfactory94.8%96.4%99.8%99.8%99.8%99.8%99.9%99.9%99.8%99.8%
Negative for intraepithelial lesion or malignancy84.2%86.8%90.4%90.8%91.2%90.4%90.6%90.4%90.1%89.1%
Non-neoplastic changes4.9%4.9%4.6%4.7%4.2%4.4%4.4%4.5%4.6%5.2%
Pathological%5.7%4.7%4.9%4.3%4.5%5.1%4.9%4.9%5.1%5.5%
Pathological (squamous cells)5.5%4.5%4.7%4.2%4.4%4.9%4.8%4.8%5.0%5.4%
ASC-US3.6%2.7%2.7%2.4%2.7%2.8%2.9%2.9%3.0%3.3%
ASC-H0.0%0.1%0.3%0.2%0.2%0.3%0.3%0.3%0.3%0.3%
LSIL1.3%1.2%1.2%1.1%1.1%1.3%1.2%1.2%1.2%1.3%
HSIL0.6%0.5%0.5%0.4%0.5%0.5%0.5%0.4%0.4%0.5%
Squamous cell carcinoma0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Pathological (glandular cells)0.2%0.1%0.1%0.1%0.1%0.2%0.1%0.1%0.1%0.1%
AGC-NOS0.2%0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.1%
AGC-favour neoplastic0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
AIS0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Adenocarcinoma0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Other0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Suspicious cells, nonspecified0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Other malignant cells0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

 

Jerman T, Ivanuš U, Florjančič M. ZORA Programme Monitoring and Evaluation. ZORA: Slovenian National Cervical Cancer Screening Programme and Registry. 2021. https://zora.onko-i.si/en/monitoring-and-evaluation/.

Accessibility(CTRL+F2)
color contrast
text size
highlighting content
zoom in